Publication: Evaluación de la seguridad de la administración intraarticular única y repetida de células madre de cordón umbilical equino (EUC-MSC) en perros jóvenes y sanos
Loading...
Official URL
Full text at PDC
Publication Date
2024-04-25
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Complutense de Madrid
Citations
Exportar
Abstract
La artrosis canina afecta a más del 20% de la población canina a partir del primer año de vida (Anderson et al., 2020). La búsqueda de terapias alternativas al empleo de antiinflamatorios no esteroideos (AINES) que alivien el dolor y mejoren la calidad de vida de los perros que padecen artrosis es, desde hace varios años, objeto de investigación. Los tratamientos intraarticulares con células madre mesenquimales (CMM), al ser aplicados directamente en el foco de dolor constituyen una alternativa eficaz pero que en la práctica son difíciles de implementar dada la dificultad de acceso a terapias avanzadas listas para su administración, esto es, sin necesidad de cultivar ningún tejido extraído del animal a tratar. Por ello, el desarrollo de un medicamento veterinario CMM para aliviar los síntomas de esta enfermedad degenerativa supondría una ventaja al poder disponer del producto de manera inmediata...
Canine osteoarthritis affects more than 20% of the canine population from the first year of life (Anderson et al., 2020). The search for alternative therapies to non-steroidal antiinflammatory drugs (NSAIDS) that relieve pain and improve the quality of life of dogs suffering from osteoarthritis has been a research objective for several years. Intraarticular treatments with mesenchymal stem cells (MSC), when applied directly to thesource of pain, constitute an efficacious alternative that is difficult to implement in practice given the difficulty of access to advanced therapies ready for administration, that is, without the need to cultivate any tissue extracted from the animal to be treated.Therefore, the development of a veterinary drug based on MSC to alleviate the symptoms of this degenerative disease would be an advantage as the product would be available immediately...
Canine osteoarthritis affects more than 20% of the canine population from the first year of life (Anderson et al., 2020). The search for alternative therapies to non-steroidal antiinflammatory drugs (NSAIDS) that relieve pain and improve the quality of life of dogs suffering from osteoarthritis has been a research objective for several years. Intraarticular treatments with mesenchymal stem cells (MSC), when applied directly to thesource of pain, constitute an efficacious alternative that is difficult to implement in practice given the difficulty of access to advanced therapies ready for administration, that is, without the need to cultivate any tissue extracted from the animal to be treated.Therefore, the development of a veterinary drug based on MSC to alleviate the symptoms of this degenerative disease would be an advantage as the product would be available immediately...
Description
Tesis inédita de la Universidad Complutense de Madrid, Facultad de Veterinaria, leída el 25/09/2023